Skip to main content

Kindergarten Vaccination Rates Hold Steady

Kindergarten vaccination coverage rates for measles, mumps, and rubella vaccine (MMR); diphtheria, tetanus, and acellular pertussis vaccine (DTaP); and varicella vaccine each approached 95% in the United States, according to the latest data from the Centers for Disease Control and Prevention (CDC).
The CDC report included 2016 to 2017 MMR, DTaP, and varicella vaccination coverage submitted by immunization programs in 48 states and the District of Columbia. Oklahoma and Wyoming did not report data.
The median vaccination coverage across the nation for two doses of MMR was 94.0%. The median vaccination rate for the state-required number of doses of DTaP was 94.5%. The median vaccination coverage rate for two doses of varicella vaccine was 93.8%.
Ranee Seither, MPH, an epidemiologist at the CDC in Atlanta, Georgia, and colleagues report that four states (California, New York, North Dakota, and Tennessee) all experienced increases in coverage of at least 1.5 percentage points for all reported vaccines. The authors published their findings in the October 13 issue of Morbidity and Mortality Weekly Report.
Since the 2011 to 2012 school year, the mean kindergarten exemption rate for MMR vaccination has remained at or below 2%. At this time, "[t]he mean percentage of kindergartners with an exemption from one or more required vaccines...is 2.0%," the authors write. They note that the exemption rate varies a great deal from state to state.
The median percentage of kindergartners attending school during a grace period or provisional enrollment was 2%, which was the same percentage as in 2015 to 2016.

Kindergarten Vaccination

Experts consider kindergarten vaccination requirements to be an excellent way to ensure children are fully vaccinated with the recommended age-appropriate vaccines. Thus, in an effort to protect students and communities against vaccine-preventable diseases, many state and local school systems require that children be fully vaccinated when they enter kindergarten. School nurses and other school personnel work with federally funded immunization programs to assess vaccination coverage and exemption status of children enrolled in public and private kindergartens.
States vary with regard to their requirements for vaccination, data collection, and definitions of grace period and provisional enrollment. Most states, however, require vaccination coverage for MMR, DTaP, and varicella.
Thirty states shared local-level school vaccination coverage. These data revealed that vaccination coverage varied at the local level.
The authors note that the data collected in their study should allow immunization programs to focus on schools with lower vaccination coverage and higher exemption levels. It should also make it possible for schools to follow up with undervaccinated students in the hopes of protecting them from vaccine-preventable diseases.
The authors have disclosed no relevant financial relationships.
Morb Mortal Wkly Rep. Published online October 12, 2017. Full text

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more